Asthma

Atrial Fibrillation

Autoimmune Diseases

Biologics

Biosimilars

Blood Cancer

Breast Cancer

COVID-19

Cardiovascular Diseases

Dermatology

Diabetes

Digital Health

Eyecare

Gene Therapy

Heart Failure

Hemophilia

Hypertrophic Cardiomyopathy (HCM)

Leukemia and Lymphoma

Liver Disease

Lung Cancer

Mental Health

Multiple Sclerosis

NSCLC

Neonatal Care

Obstetrics-Gynecology & Women's Health

Oncology

Opioids

Pediatrics

Plaque Psoriasis

Secondary Progressive Multiple Sclerosis: Patient Impact and Coverage Implications for New Therapies

Population Health

Post-Acute Care

Prescription Digital Therapeutics

Pulmonary Arterial Hypertension

Reproductive Health

Respiratory Conditions

Sleep Disorders

Solid Tumors

Spinal Muscular Atrophy

Substance Use Disorder

The Improving Patient Access Podcast

Type I Diabetes

Type II Inflammation

Ulcerative Colitis

Urology

Urothelial Carcinoma

Vaccines

Vaccines: 2023 Year in Review

Women's Health

News

Media

Between the Lines

Expert Interviews

K-Cast

Medical World News

Podcasts

Population Health Perspectives

Conferences

Partners

Publications

All Publications

MHE Publication

Formulary Watch Supplements

Supplements And Featured Publications

Events

2024 PBMI Annual National Conference

PBMI MAP

Virtual Events

CME/CE

Resources

PBM Leaders

Subscribe

Peter Wehrwein has been the lead editor of Managed Healthcare Executive since February 2020.

Videos

Leaders at UC Davis Health created an emerging therapies committee to review and prepare for the wave of treatments that cost millions of dollars.

Do P&T Committees Need Help With Cell and Gene Therapy? | AMCP 2024

Articles

Joseph Zabinski, PhD, MEM, vice president, head of commercial strategy and AI, OM1, chatted with MHE editors on the significance of patient acceptance in AI adoption in healthcare, overall and in the dermatology space, stressing trust and transparency. 

Joseph Zabinski Advocates for Patient Trust in AI Adoption in Dermatology Care

After the onboarding of cell and gene therapy bogged using normal pharmacy and therapeutics (P&T) committee procedures, UC Davis Health set up an emerging therapeutics committee to streamline and speed up the process of delivery expensive cell and gene therapies.

Emerging Therapies Committee at UC Davis Hits the Accelerator Not the Brake | AMCP 2024

This decision may lead to faster approval of new treatments for multiple myeloma.

FDA Advisory Committee Supports New Surrogate Endpoint To Assess Multiple Myeloma Treatments

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, insights, and strategies to pursue value-driven solutions.

About Us

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Managed Healthcare Executive

Facebook

Twitter

LinkedIn

Resource Centers

Eye Care

Spotlight

2023 PBMI Annual National Conference

2024 Emerging Leader Nominations

AMCP Annual

ASRS

Asembia’s Specialty Pharmacy Summit

Business

Business Strategy

Chronic Disease

Consumers

Drug Costs

Drug Pipeline

Formulary

Health Management

Health/Disease Strategy

Hospitals & Providers

Industry Analysis

Pharmacy

Politics and Policy

Practice Management

Reimbursement

Technology

1rem

Authors

Jonathan Lahn

Articles